Prelude Therapeutics Incorporated (PRLD)

Market Cap	320.98M
Revenue (ttm)	n/a
Net Income (ttm)	-115.44M
Shares Out	47.90M
EPS (ttm)	-2.44
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	19,420
Open	6.40
Previous Close	6.40
Day's Range	6.22 - 6.67
52-Week Range	3.87 - 8.90
Beta	0.44
Analysts	Buy
Price Target	10.20 (+63.99%)
Earnings Date	May 9, 2023

About PRLD

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high k...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 25, 2020
• Employees: 120
• Stock Exchange: NASDAQ
• Ticker Symbol: PRLD

Analyst Forecast

According to 11 analysts, the average rating for PRLD stock is "Buy." The 12-month stock price forecast is $10.2, which is an increase of 63.99% from the latest price.

Price Target

$10.2

(63.99% upside)

Analyst Consensus: Buy